Zum Inhalt springen

Cover E Brasilienstudie 2012 smallBUKO Pharma-Kampagne has carefully examined the business behaviour of Bayer Health Care, Boehringer Ingelheim and Baxter in Brazil. Our conclusions: whereas Baxter´s portfolio exclusively comprises rational drugs, the manufacturers Bayer and Boehringer Ingelheim sell a considerable number of nonsensical preparations. Even the majority of the blockbusters declared inventive do not offer advantageous treatment for the patients. They are unaffordable and a waste of scarce resources. The companies examined conduct a large number of research projects in brazil. They are focused on lucrative fields such as cardiovascular diseases, cancer and diabetes – diseases which are increasingly common in Brazil. For neglected diseases, which are also still common in Brazil, the companies don´t show much committment.

Download: Brochure [PDF/2,0 mB]

Wenn Sie sich regelmäßig über die Pharma-Problematik informieren wollen, sollten Sie den Pharma-Brief abonnieren.

Jetzt abonnieren

Wir überlassen Big Pharma nicht das Feld! Mit Ihrer Spende bereiten Sie uns und unserer Arbeit Boden...

Jetzt spenden